trial · primary record
Glofitamab
Diffuse Large B Cell Lymphoma Refractory
| Phase | Phase 2 |
|---|---|
| Status | RECRUITING |
| Sponsor | Unknown |
| Enrolment | 40 |
| Primary completion | 2031-12-15 |
| Primary endpoint | To evaluate the efficacy of glofitamab when used as a bridge to and/or consolidation post-transplant for patients with relapsed/refractory B-cell lymphomas (DLBCL or transformed low grade B cell lymphoma) fit and eligible for ASCT |
| Registry ID | NCT07387848 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-29T14:33:56.502Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT07387848
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.
Same entity, elsewhere in the suite
- Glofitamab · compound